Compare CDLR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDLR | TRVI |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2023 | 2019 |
| Metric | CDLR | TRVI |
|---|---|---|
| Price | $24.88 | $17.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 57.4K | ★ 1.4M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.56 | N/A |
| Revenue Next Year | $32.79 | N/A |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $6.98 |
| 52 Week High | $30.01 | $20.22 |
| Indicator | CDLR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 41.56 |
| Support Level | $24.92 | $16.24 |
| Resistance Level | $25.38 | $19.30 |
| Average True Range (ATR) | 0.44 | 0.75 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 67.79 | 26.70 |
Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.